Epithelioid mesothelioma versus primary pulmonary adenocarcinoma

Markers positive in adenocarcinoma but negative in mesothelioma have now been supplemented with a range of markers positive in mesothelioma and negative in adenocarcinoma. Generally, a panel should contain members of both groups. The following panels have been recommended, based on studies of panels of markers:

				Reference
	Summary17	sensitivity	specificity	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
34bE12											O					O
44-3A6								O
Amylase					O
AUA1										O
B72.3	A,=1 (positive in adenocarcinoma; recommended as a first-line marker with BerEP4 or MOC1 as alternatives)	80%	91%	1	O	1		1	2		O	O		O			O			=1	=1
BerEP4	A,=1 (positive in adenocarcinoma; recommended as a first-line marker with B72.3 or MOC1 as alternatives)	80%	88%		1	1		O	1	=1	1	O	2	O		1		O	2	=1	=1
Ber-H2											O
BG-8	A,2 (positive in adenocarcinoma; recommended as a second-line marker)	88%	89%						1											2
Blood-group related antigens A, B &H					3
BMA-120					O
Ca 125				O						O
Ca 19.9	A,2 (positive in adenocarcinoma; recommended as a second-line marker)	56%	99.5%							1										2
Calretinin	M,1 (positive in epithelioid mesothelioma; recommended as a first-line marker)	80%	86%					O	O	O		1	1	1	O	=1		O	2	1	=1
Cam 5.2											O
CD 44H														O				O
CD44S	M,O (positive in epithelioid mesothelioma, but not recommended)	66%	61%																	O
CD138	A (positive in adenocarcinomanot of proven value as a marker)	55%	92%
CEA	A,1 (positive in adenocarcinoma; recommended as a first-line marker)	84%	97.5%	1	4	1	1	1	1	1	O	O	1	1		=1	O	O	2	1	=1
CK4							O
CK5/6	M,=1 (positive in epithelioid mesothelioma; recommended as a first-line marker with WT1 as an alternative)	80%	83%				O									1			2	=1	=1
CK7					O		O
CK8							O
CK8/18/19							O
CK10							O
CK13							O
CK13/16							O
CK14							O
CK16							O